Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

<p>Merestinib and LY2874455 inhibit MET-activated signal transduction. A, AML cell lines treated with merestinib and LY2874455 in vitro for 1 hour exhibited decreased levels of pSTAT3 and pSTAT5 by phospho-flow cytometry. Standard errors are shown for KG1a (n=3) and HEL (n=2) cell lines. Repre...

Descrición completa

Gardado en:
Detalles Bibliográficos
Autor Principal: Evan C. Chen (15054014) (author)
Outros autores: Helen Gandler (15054017) (author), Isidora Tošić (15054020) (author), Geoffrey G. Fell (15054023) (author), Ashlee Fiore (15054026) (author), Olga Pozdnyakova (15054029) (author), Daniel J. DeAngelo (15031959) (author), Ilene Galinsky (15054032) (author), Marlise R. Luskin (15054035) (author), Martha Wadleigh (15054038) (author), Eric S. Winer (15054041) (author), Rebecca Leonard (15054044) (author), Kelsey O'Day (15054047) (author), Adrienne de Jonge (15054050) (author), Donna Neuberg (15038318) (author), A. Thomas Look (14951403) (author), Richard M. Stone (15054053) (author), David A. Frank (14961075) (author), Jacqueline S. Garcia (15043140) (author)
Publicado: 2025
Subjects:
Cancer
Therapeutic Research and Development
Clinical Research and Trials
Clinical Trial Results
Phase I clinical trials
Drug Targets
Protein kinase & phosphatase drug targets
Hematological Cancers
Leukemias
Pharmacology
Pharmacokinetics and pharmacodynamics
Precision Medicine
Small Molecule Agents
Kinase inhibitors
Translational Research
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
Sexa o primeiro en deixar un comentario!
You must be logged in first

Títulos similares